Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC) 2Bites and Stings 1Adenocarcinoma 1

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2AMG 757 2durvalumab 1dostarlimab 1cemiplimab 1atezolizumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Hydroxyurea 1Etoposide 1Etanercept 1Carboplatin 1Androgen Receptor Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bites and Stings × Androgen Receptor Antagonists × Clear all
NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡